Original Source(s)
Related Content
FDA expands gastroesophageal cancer options
Phase 3 findings showed longer median progression-free survival with zanidatamab-containing regimens vs trastuzumab plus chemotherapy.
August 25, 2026
-
2 min
Neurogenic progression may falter in MDD
Postmortem multiomic analyses showed more quiescent neural stem cells and fewer neuroblasts, alongside broader hippocampal molecular changes.
August 26, 2026
-
4 min